Skip to main content

Table 2 Overall response

From: Combination therapy with Olaratumab/doxorubicin in advanced or metastatic soft tissue sarcoma -a single-Centre experience

 all patientspatients receiving surgery
outcomen = 32n = 9
PD n (%)21 (65.6)3 (33.3)
PR n (%)4 (12.5)4 (44.4)
SD n (%)7 (21.9)2 (22.2)
  1. PR partial response; SD stable disease; PR progressive disease
  2. Response was assessed based on imaging (CT or MRI) scans in analogy to the RECIST v1.1. criteria